Literature DB >> 12569242

The ALLHAT trial: strengths and limitations.

Robert H Fagard.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12569242     DOI： 10.1097/00004872-200302000-00003

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  4 in total

1.  Information from drug companies and opinion leaders.

Authors:  Alessandro Liberati; Nicola Magrini
Journal:  BMJ       Date:  2003-05-31

2.  [Prevention of arteriosclerosis. Importance of the treatment of arterial hypertension].

Authors:  G Bönner; D B Gysan; G Sauer
Journal:  Z Kardiol       Date:  2005

3.  Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: a pilot study.

Authors:  Shaymaa Abdalwahed Abdulameer; Mohanad Naji Sahib; Noorizan Abd Aziz; Yahaya Hassan; Hadeer Akram Abdul Alrazzaq; Omar Ismail
Journal:  Patient Prefer Adherence       Date:  2012-01-31       Impact factor: 2.711

4.  Back to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribing.

Authors:  Atle Fretheim
Journal:  BMC Fam Pract       Date:  2003-12-23       Impact factor: 2.497
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.